Nuclera has announced that it has appointed Joseph Bertelsen as chief commercial officer (CCO).

BenevolentAI has announced that Dr Daniel Neil, current chief technology officer (CTO) is stepping down, to be succeeded by Dr James Malone, who joins the company in April.

Vynamic has announced the appointment of Gemma Pfister as head of life sciences Europe.

Parexel has announced that its CEO, Jamie MacDonald will retire, with the company’s current chief operating and growth officer Peyton Howell taking over as CEO, effective 15 May 2024.

Amylyx Pharmaceuticals has announced that it has appointed Andrew Caldwell to general manager UK and Ireland.

French biotech company StromaCare has announced the appointment of Georges Rawadi as chief executive officer (CEO).

AdhereTech has announced that it has appointed Paul Sekhri to its board of directors, having begun his new role on 7 February 2024.

Cuttsy+Cuttsy has announced the appointment of Jon Hume as commercial director, taking his new role from 1 March 2024.

BenevolentAI has announced that it has appointed Dr Joerg Moeller MD PhD as its new chief executive officer and executive board member, the changes will be effective immediately.

Sosei Group corporation has announced the appointment of Toshihiro Maeda as chief operating officer (COO).

X-Chem has announced that it is making changes to its executive management team, with Karen Lackey, the current chief scientific officer (CSO), becoming chief executive officer (CEO) and Matthew Clark, the current CEO pivoting to the role of president and CSO.

Cellular Origins has announced that it has appointed Peter Crossley as chief operating officer (COO).